Treatment · International
JAMA Psychiatry: efficacy and safety of xanomeline-trospium chloride in schizophrenia
The pivotal randomized trial that supported the first new mechanism of action for schizophrenia in seventy years.
These are short summaries of research and reporting published elsewhere. We link to the original. Mental Hum does not report these stories.
Mental Hum is owned and operated by Dean Shaban
This is the pivotal randomized clinical trial published in JAMA Psychiatry supporting the FDA approval of Cobenfy (xanomeline-trospium chloride), the first schizophrenia drug in seven decades acting on a non-dopaminergic mechanism.
It is the primary source paper behind much of the lay coverage of the approval.
Read the full JAMA Psychiatry article for the trial design and outcomes.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.